137 related articles for article (PubMed ID: 1926674)
21. [The use of intravesical oxybutynin hydrochloride in patients with neurogenic bladder managed by intermittent catheterization].
Yokoyama O; Ishiura Y; Nakamura Y; Ohkawa M
Hinyokika Kiyo; 1995 Jul; 41(7):521-4. PubMed ID: 7668182
[TBL] [Abstract][Full Text] [Related]
22. Postpubertal urodynamic and upper urinary tract changes in children with conservatively treated myelomeningocele.
Almodhen F; Capolicchio JP; Jednak R; El Sherbiny M
J Urol; 2007 Oct; 178(4 Pt 1):1479-82. PubMed ID: 17706702
[TBL] [Abstract][Full Text] [Related]
23. [Effects of trospium chloride on the lower urinary tract function].
Suzuki T; Nishizawa O; Sugaya K; Kohama T; Matsuzaki A; Fukuda T; Tsukada T; Harada T; Tsuchida S
Hinyokika Kiyo; 1990 Sep; 36(9):1047-51. PubMed ID: 2239610
[TBL] [Abstract][Full Text] [Related]
24. [Clinical trial to evaluate trospium chloride (Uraplex) effectiveness and tolerance in patients with detrusor instability incontinence and its impact on quality of life].
Fuertes ME; García Matres MJ; González Romojaro V; de la Rosa S; Anguera Vila A; de la Peña J; Leiva Galvis O; Sánchez Chapado M
Arch Esp Urol; 2000 Mar; 53(2):125-36. PubMed ID: 10802918
[TBL] [Abstract][Full Text] [Related]
25. Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms.
Zinner NR; Dmochowski RR; Staskin DR; Siami PF; Sand PK; Oefelein MG
Neurourol Urodyn; 2011 Sep; 30(7):1214-9. PubMed ID: 21462240
[TBL] [Abstract][Full Text] [Related]
26. Bioavailability of trospium chloride after intravesical instillation in patients with neurogenic lower urinary tract dysfunction: A pilot study.
Walter P; Grosse J; Bihr AM; Kramer G; Schulz HU; Schwantes U; Stöhrer M
Neurourol Urodyn; 1999; 18(5):447-53. PubMed ID: 10494116
[TBL] [Abstract][Full Text] [Related]
27. An artificial somatic-autonomic reflex pathway procedure for bladder control in children with spina bifida.
Xiao CG; Du MX; Li B; Liu Z; Chen M; Chen ZH; Cheng P; Xue XN; Shapiro E; Lepor H
J Urol; 2005 Jun; 173(6):2112-6. PubMed ID: 15879861
[TBL] [Abstract][Full Text] [Related]
28. Trospium chloride for the treatment of detrusor instability in children.
Lopez Pereira P; Miguelez C; Caffarati J; Estornell F; Anguera A
J Urol; 2003 Nov; 170(5):1978-81. PubMed ID: 14532838
[TBL] [Abstract][Full Text] [Related]
29. Combined antimuscarinics for treatment of neurogenic overactive bladder.
Nardulli R; Losavio E; Ranieri M; Fiore P; Megna G; Bellomo RG; Cristella G; Megna M
Int J Immunopathol Pharmacol; 2012; 25(1 Suppl):35S-41S. PubMed ID: 22652160
[TBL] [Abstract][Full Text] [Related]
30. Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia.
Madersbacher H; Stöhrer M; Richter R; Burgdörfer H; Hachen HJ; Mürtz G
Br J Urol; 1995 Apr; 75(4):452-6. PubMed ID: 7788255
[TBL] [Abstract][Full Text] [Related]
31. Effect of controlled-release oxybutynin on neurogenic bladder function in spinal cord injury.
O'Leary M; Erickson JR; Smith CP; McDermott C; Horton J; Chancellor MB
J Spinal Cord Med; 2003; 26(2):159-62. PubMed ID: 12828295
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of once-daily trospium chloride extended-release in male patients with overactive bladder.
MacDiarmid SA; Ellsworth PI; Ginsberg DA; Oefelein MG; Sussman DO
Urology; 2011 Jan; 77(1):24-9. PubMed ID: 20970833
[TBL] [Abstract][Full Text] [Related]
33. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study.
Schurch B; de Sèze M; Denys P; Chartier-Kastler E; Haab F; Everaert K; Plante P; Perrouin-Verbe B; Kumar C; Fraczek S; Brin MF;
J Urol; 2005 Jul; 174(1):196-200. PubMed ID: 15947626
[TBL] [Abstract][Full Text] [Related]
34. [Topical treatment with oxybutynin chloride in neurogenic incontinence].
López Pereira P; Martínez MJ; Muguerza R; Jaureguizar E
Cir Pediatr; 1993 Jan; 6(1):29-31. PubMed ID: 8499234
[TBL] [Abstract][Full Text] [Related]
35. [Neurogenic urinary incontinence: current treatment concepts].
Madersbacher H
Urologe A; 1990 Jul; 29(4):176-84. PubMed ID: 2205038
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomized, double-blind, multicentre clinical trial.
Cardozo L; Chapple CR; Toozs-Hobson P; Grosse-Freese M; Bulitta M; Lehmacher W; Strösser W; Ballering-Brühl B; Schäfer M
BJU Int; 2000 Apr; 85(6):659-64. PubMed ID: 10759661
[TBL] [Abstract][Full Text] [Related]
37. [Comparative studies of the effect of mictonorm (propiverin hydrochloride) and Spasuret (flavoxate hydrochloride) on the bladder detrusor muscle].
Wehnert J; Sage S
Z Urol Nephrol; 1989 May; 82(5):259-63. PubMed ID: 2665385
[TBL] [Abstract][Full Text] [Related]
38. Long-term effects of repeated intradetrusor botulinum neurotoxin A injections on detrusor function in patients with neurogenic bladder dysfunction.
Pannek J; Göcking K; Bersch U
BJU Int; 2009 Nov; 104(9):1246-50. PubMed ID: 19426192
[TBL] [Abstract][Full Text] [Related]
39. Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections.
Gamé X; Castel-Lacanal E; Bentaleb Y; Thiry-Escudié I; De Boissezon X; Malavaud B; Marque P; Rischmann P
Eur Urol; 2008 Mar; 53(3):613-8. PubMed ID: 17804150
[TBL] [Abstract][Full Text] [Related]
40. Baseline incontinence severity is predictive of the percentage of patients continent after receiving once-daily trospium chloride extended release.
Staskin DR; Cardozo L
Int J Clin Pract; 2009 Jun; 63(6):973-6. PubMed ID: 19459997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
